Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) has signed a new joint study agreement with Kumagaya General Hospital (Location: Kumagaya, Saitama, Chairman: Ikuo Hashimoto). With the conclusion of this agreement, Craif will begin a study to analyze “Clinical Information and Biomaterials Related to the Pathogenesis and Pathology of Gastrointestinal and Breast Cancer” (principal investigator: Dr. Masaya Yokoyama, Department of Surgery), and “miRNA in Body Fluid (urine, saliva, and blood) of Healthy Personnel” (principal investigator: Dr. Yasutaka Kato, Department of Diagnostic Pathology).

■ Outline of the two studies

1.”Analysis of Clinical Information and Biomaterials Related to the Pathogenesis and Pathology of Gastrointestinal and Breast Cancer”
Gastrointestinal and breast cancer are often intractable and associated with reduced QOL. Therefore, there was always a desire to elucidate the etiology, and establish customized preventive medicine. In this study, we will clarify multiple tumor-related genes and miRNAs expression through various analyses, and contribute to the implementation of customized medicine in gastrointestinal and breast cancer.

2.”Analysis of the miRNA in Body Fluid (Urine, Saliva, and Blood) of Healthy Personnel”
In recent years, studies have been conducted to evaluate the risk of malignant cancer by analyzing components in body fluids such as blood, urine, and saliva. However, in order to implement this technology in a clinical situation, understanding healthy personnel’s data is inevitable. In this research, we will capture and analyze miRNAs from body fluids (urine, saliva, and blood) of healthy people, and contribute to the clinical implementation for early detection of malignant cancers using body fluids.